Manama: The National Health Regulatory Authority (NHRA) has announced the withdrawal and suspension of registration of the pharmaceutical product “PROTON 40mg E.C TABLET – PROTON 20mg E.C TABLET”, produced by the Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO). The move is based on the warning issued by the Saudi Food and Drug Authority (SFDA) on March 12, 2021. The NHRA indicated said that it has withdrawn the medicine from the Kingdom, and suspended its registration because it does not match the original product. The NHRA recommended the health authorities to withdraw the product as soon as it is available to them, calling on the medicine users to contact their doctors to receive the alternative medication.
Trending
- BIC set for back-to-back days of thrills with Kanoo Motors Rolling Drag, Open Track
- Saudi Crown Prince, Amir of Qatar attend signing of high-speed rail project agreement
- Over 900 dead in Sumatra floods as residents struggle to reach aid
- HH Shaikh Nasser bin Hamad: “GPCA” Forum reflects Bahrain’s commitment to developing energy sectors and industrial innovation
- Interior Minister underscores national and international efforts on International Anti-Corruption Day; 193 cases investigated in Bahrain during 2025
- HM King attends opening of Mara’ee 2025
- ILA Sneha Annual Day 2025: A Winter Wonderland of Talent, Service, and Joy
- HH Shaikh Nasser bin Hamad Al Khalifa announces record production of the refinery one year after its inauguration
